Author

Indra Purevjal

Observed name: I. Purevjal

Institution: Takeda Oncology (United States)

Observed institutions: Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Takeda (United States), Dana-Farber Brigham Cancer Center, Takeda Oncology (United States)

OpenAlex ID: A5033070489

Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting

2018 · Auayporn Nademanee, Anna Sureda, et al. · Transplantation and Cellular Therapy · 38

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

2020 · David Straus, Graham Collins, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 19

Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.

2018 · David J. Straus, Graham P. Collins, et al. · Journal of Clinical Oncology · 6

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

2018 · John Radford, Joseph M. Connors, et al. · Blood · 2

Plasma exposure to metabolites of monomethyl auristatin E (MMAE) in patients with relapsed/refractory Hodgkin lymphoma (HL) treated with brentuximab vedotin (BV)

2016 · Adedigbo A. Fasanmade, Judith Kinley, et al. · Ghent University Academic Bibliography (Ghent University)

A study of complementary therapies in men receiving radiation therapy for prostate cancer: A randomized feasibility trial

2007 · C. Beard, E. Dean-Clower, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 65

H-index: 3

I10-index: 2